Coronary disease & ACSCohort study
Timing of Bleeding and Ischemic Events in High–Bleeding Risk Patients Treated With 1-Month Dual Antiplatelet Therapy (DAPT)
- Pooled patient-level analysis of 7 prospective studies
- patient-level data
Authors' conclusion
Among HBR patients undergoing PCI treated with 1-month DAPT, the risk for major bleeding and MACE is highest in the first 30 days. MACE remain consistently more frequent than bleeding after the first month, when event rates stabilize over time while on single antiplatelet therapy.
Study context
- Population
- High bleeding risk (HBR) patients treated with percutaneous coronary intervention (PCI) and 1-month DAPT
- Participants
- 7,266 patients · 7 prospective studies
- Exposure
- Timing of major bleeding vs major adverse cardiovascular events (MACE) after PCI
- Outcome
- Timing of major bleeding (BARC 3–5) and MACE
- Follow-up
- 1 year after PCI
Main finding
As reported in the abstract
- Bleeding Academic Research Consortium (BARC) 3–5 bleeding, overall
- 284 (4.0%)
- BARC 3–5 bleeding ≤30 days after PCI
- 73 (1.0%)
- BARC 3–5 bleeding >30 days after PCI
- 211 (2.9%)
- MACE, overall
- 433 (6.0%)
- MACE ≤30 days after PCI
- 64 (0.9%)
- MACE after 30 days
- 369 (5.1%)
- First 30 days: MACE vs BARC 3–5 bleeding rates, no significant difference
- 22.3% vs 25.7%; P = 0.407
- 31–90 days: MACE rates significantly higher than BARC 3–5 bleeding
- 7.2% vs 4.9%; P = 0.024
- 91–365 days: MACE rates significantly higher than BARC 3–5 bleeding
- 5.3% vs 3.1%; P < 0.001
Observational data: associations, not effects.
Original publication
Timing of Bleeding and Ischemic Events in High–Bleeding Risk Patients Treated With 1-Month DAPT. JACC Cardiovasc Interv. Published 27 July 2026. doi:10.1016/j.jcin.2026.05.027
Summarised from the published abstract; every number is checked against it